Corrigendum to ‘Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease’ (EBioMedicine (2019) 47 (446–456), (S2352396419305912), (10.1016/j.ebiom.2019.08.069))

La Tonya J. Hickson, Larissa G.P. Langhi Prata, Shane A. Bobart, Tamara K. Evans, Nino Giorgadze, Shahrukh K. Hashmi, Sandra M. Herrmann, Michael D. Jensen, Qingyi Jia, Kyra L. Jordan, Todd A. Kellogg, Sundeep Khosla, Daniel M. Koerber, Anthony B. Lagnado, Donna K. Lawson, Nathan K. LeBrasseur, Lilach O. Lerman, Kathleen M. McDonald, Travis J. McKenzie, João F. PassosRobert J. Pignolo, Tamar Pirtskhalava, Ishran M. Saadiq, Kalli K. Schaefer, Stephen C. Textor, Stella G. Victorelli, Tammie L. Volkman, Ailing Xue, Mark A. Wentworth, Erin O. Wissler Gerdes, David B. Allison, Stephanie L. Dickinson, Keisuke Ejima, Elizabeth J. Atkinson, Marc Lenburg, Yi Zhu, Tamara Tchkonia, James L. Kirkland

Research output: Contribution to journalComment/debate

4 Scopus citations

Abstract

In this article, a re-analysis of the raw data has been conducted, which means that some conclusions presented in the paper have changed. The authors have written a Corrigendum which is appended (Appendix 1). In the interests of transparency, they have included de-identified data from the original article in Appendix 2.

Original languageEnglish (US)
Article number102595
JournalEBioMedicine
Volume52
DOIs
StatePublished - Feb 2020

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Corrigendum to ‘Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease’ (EBioMedicine (2019) 47 (446–456), (S2352396419305912), (10.1016/j.ebiom.2019.08.069))'. Together they form a unique fingerprint.

  • Cite this